Eli Lilly’s oral weight-loss drug Foundayo recorded 1,390 prescriptions for the week ending April 10.
Analysts estimate this total reflects only two days of actual data.
Eli Lilly shares rose approximately 2% in early trading on April 17 following the report.
Novo Nordisk’s rival Wegovy pill logged 3,071 prescriptions during its first full week of launch.
Market experts expect Foundayo’s long-term competitive standing to clarify as prescription volume tracks over coming weeks.